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Abstract 
Background The objectives were to assess the feasibility and validity of using markers of 
dementia-related health as indicators of dementia progression in primary care, by assessing the 
frequency they are recorded and by testing the hypothesis they are associated with recognised 
outcomes of dementia. The markers, in 13 domains, were derived previously through literature 
review, expert consensus, and analysis of regional primary care records. 
Methods The study population were patients with a recorded dementia diagnosis in the Clinical 
Practice Research Datalink, a UK primary care database linked to secondary care records. 
Incidence of recorded domains in the 36 months after diagnosis was determined. Associations of 
recording of domains with future hospital admission, palliative care, and mortality were derived. 
Results There were 30,463 people with diagnosed dementia. Incidence of domains ranged from 
469/1000 person-years (Increased Multimorbidity) to 11/1000 (Home Pressures). An increasing 
number of domains in which a new marker was recorded in the first year after diagnosis was 
associated with hospital admission (hazard ratio for ≥4 domains versus no domains 1.24; 95% CI 
1.15, 1.33), palliative care (1.87; 1.62, 2.15), and mortality (1.57; 1.47, 1.67). Individual domains 
were associated with outcomes with varying strengths of association.
Conclusions
Feasibility and validity of potential indicators of progression of dementia derived from primary 
care records is supported by their frequency of recording and associations with recognised 
outcomes. Further research should assess whether these markers can help identify patients with 
poorer prognosis in order to improve outcomes through stratified care and targeted support.
Introduction
Over 850,000 people in the UK are estimated to live with dementia, projected to rise to 1.6million 
by 2040.1 Dementia has a substantial impact on the lives of individuals. The UK government has 
prioritised early recognition and treatment, in order to prolong independence, delay and reduce 
admissions to nursing home and hospital, and prolong survival.2-4 Primary care has a pivotal role 
in achieving these aims,5-7 particularly in the UK where most people are registered with a general 
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There have been primary care studies on “case-finding” and identifying risk factors for dementia 
onset,8,9 but little research on the course and prognosis of patients with dementia in primary care. 
One potential source of information on the course of dementia are primary care electronic health 
records (EHR) that contain coded reasons (morbidities, symptoms) for consultation and 
management (for example, prescriptions, referrals, tests, investigations). While EHR can provide 
data on “hard” long-term outcomes such as hospital admissions and mortality, it is not known 
whether indicators of disease progression can be identified from primary care EHR. 
A set of indicators in primary care could support case management decisions, contribute to 
understanding of prognosis, improve communication with patients and caregivers, and inform 
planning and monitoring of care at a population level. They could improve the efficiency of 
intervention studies which currently rely on intensive and costly follow-up assessments and long-
term outcomes such as mortality. In the first part of the MEasurement of Dementia DIsease 
progression in Primary care (MEDDIP) study, we established a set of markers of dementia-related 
health that may be recorded in UK primary care EHR,10 drawing on a rapid literature review, 
expert consensus, and scrutiny of a regional primary care EHR database. The set has 63 markers in 
13 domains (Table 1). 
The objectives of this part of the MEDDIP study were to assess the feasibility and validity of these 
markers and domains as indicators of progression for people with dementia. Feasibility was 
assessed by estimating the prevalence and incidence of recorded markers and domains within 
primary care EHR at time of, and early after, diagnosis of dementia. Validity was assessed by 
estimating the association of recording of these domains with established longer-term outcomes 
(hospital admission, palliative care, early mortality) under the hypothesis (construct validity) that 
patients with new recorded markers/domains early on in their dementia course will have a higher 
risk of poor outcomes. 
Methods
Setting
This was a cohort study set within the Clinical Practice Research Datalink (CPRD) GOLD, a 
database of longitudinal pseudonymised primary care data from 17 million patients across a 
network of UK general practices. The study was approved by the CPRD Independent Scientific 
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Study population
Patients with a recorded diagnosis of Alzheimer’s disease, vascular dementia, Lewy Body 
dementia, Parkinson’s dementia, fronto-temporal dementia, mixed, and unspecified dementia 
between 1998-2017 were included. Diagnosis of dementia was based on a Read code list 
developed previously through consensus of GP and EHR researchers,11 and code lists used in other 
studies.12-14 Read codes are the main method of recording morbidity and processes of care within 
UK primary care. Coding of dementia in UK primary care EHR has been validated previously.15 
Patients with a Read code suggesting a history of any type of dementia (for example, “H/O: 
(History of) dementia”, “Dementia annual review”) prior to the date of first dementia diagnosis 
(index date) or a recorded prescription for an anti-dementia drug (Donepezil, Galantamine, 
Memantine, Rivastigmine) prior to the index date were excluded. Read code lists are available 
from www.keele.ac.uk/mrr.
Patients had to have three years of up to standard data in CPRD prior to the index date and one 
year post index date as a minimum follow-up time to capture progression of dementia (Figure 1a). 
All patients were required to have linked Hospital Episode Statistics (HES) admissions, 
neighbourhood deprivation (Index of Multiple Deprivation 201516), and mortality (via the Office 
for National Statistics [ONS]) data. This encompasses around 50% of patients in CPRD GOLD 
(all in England).
Markers and domains
Code lists for markers utilised previous UK-based EHR research studies,17-24 existing databases of 
Read code lists,25,26 and searches of the UK Clinical Terminology Read Code Browser. The 
markers and associated domains are shown in Table 1. The first recording of each marker in the 
period from two years before the index date to three years after was identified. The exception was 
for the Increased Multimorbidity domain which was measured for each 12-month period within 
those five years and is a general measure of multimorbidity (increase in number of different drugs 
prescribed, based on British National Formulary sections, compared to the previous 12-month 
period). The Dementia-related Drug domain was based on a new prescribed drug specific to 
dementia (Donepezil, Galantamine, Memantine, Rivastigmine) or a drug that may be used in 
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Outcomes
The outcomes were first all-cause hospital admission, palliative care, and all-cause mortality 
measured until the end of follow-up defined as earliest of date of death, end of study (December 
31st 2018), and date of end of up-to-standard records in CPRD. Hospital admission from any 
cause was based on recorded date of admission in the linked HES data after diagnosis. Palliative 
care was defined based on Read coded indication of palliative care or coded indication of being 
within 12 months of end of life.27 Patients with such a Read code prior to the index date were 
excluded from analysis of this outcome. All-cause mortality was defined as the earliest record of 
death from CPRD or ONS mortality data. 
Baseline covariates
Covariates were age at index date, sex, year of diagnosis, geographical region, deprivation, and 
lifestyle factors. Deprivation was measured by the Index of Multiple Deprivation 2015, a 
composite measure of neighbourhood deprivation.16 Lifestyle factors (body mass index, smoking 
status, alcohol consumption) were based on the most recent measurement in the five years prior to 
the index date. 
Analysis
Time periods for each analysis are shown in Figure 1. When analysing associations with 
outcomes, markers and domains were measured prior to occurrence of that outcome.
Feasibility: Prevalence and incidence of markers and domains
The prevalence of recorded markers at time of diagnosis, defined as the proportion of all people in 
the study population with a record of the marker in the 24 months prior to the index date, was 
determined. Incidence per 1000 person-years (py) at risk of recorded markers in the 36 months 
after the index date in those with no record of the marker in the 24 months prior to index date was 
determined (Figure 1b). Prevalences and incidences of domains were also calculated. Incidence 
was defined for 12 domains as a record of any marker in the domain after index date with no 
previous record of any marker from that domain. For the remaining domain, a first increase in the 
number of different drugs prescribed in a 12 month period compared to the previous 12 months 
indicated increased multimorbidity 
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Associations of domains with outcomes were assessed in two ways. First, we examined the 
associations of individual domains recorded up to three years after diagnosis (but before outcome). 
The incidence after index date of each of the outcomes (hospital admission, palliative care, 
mortality) per 1000py at risk were calculated. Cox proportional hazards models estimated the 
association of having any recorded marker in a domain with each outcome, adjusted for age and 
gender. The proportional hazards assumption was visually assessed using (log-log transformed) 
survival curves. Domain (exposure) was included as a time varying covariate. Follow-up started at 
index date and baseline exposure was defined as a record of any marker within the domain in the 
24 months prior to the index date and exposure status could change from unexposed at baseline to 
exposed over the first three years of follow-up (Figure 1c). It was assumed that, once the patient 
was exposed (i.e. had a record of any marker from that domain), they were exposed for the 
remainder of follow-up (until censored or outcome occurred). As Increased Multimorbidity was 
defined over a 12 month period, date of changed exposure was the end of the 12 month period i.e. 
1, 2 or 3 years after the index date. 
Validity: Accumulation of markers and association with outcomes
Our second approach to examine associations of domains with outcomes assessed the relationship 
of accumulation of new markers early after diagnosis with outcomes. For this analysis, for most 
domains, a record of any previously unrecorded marker in a domain indicated progression even if 
another marker within that domain had previously been recorded. The Daily Functioning domain 
has a hierarchical subset of markers (Mobility-limited, Mobility-severe, Wheelchair, Bedbound), 
and a marker was counted only if a more restricted mobility marker had not previously been used. 
In the Safety domain any fall was counted regardless of previously recorded falls. For each patient 
we determined the cumulative number of domains with at least one marker that was first recorded 
in the 12 months after the index date (i.e. no record of that marker in the 24m prior to the index 
date, even if other markers in that domain had been recorded).  Follow-up of outcomes started at 
12 months post-index date (Figure 1d). Cox proportional hazards models determined the 
association of cumulative number of domains in that first 12 months with the outcomes adjusted 
for baseline covariates. Analysis was repeated for cumulative number of domains over the 36 
months after index date in those with at least 36 months of follow-up, with follow-up of outcomes 
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Sensitivity analyses assessed whether any improvement in completeness of recording of markers 
over time influenced results by restricting the analysis to patients diagnosed with dementia from 
2010 onwards.
All analyses were performed in Stata v15.
Results
30,463 patients with dementia met our inclusion criteria. Baseline patient characteristics are given 
in table 2. Mean age was 81.6 (SD 7.86) years and 63% were female. Median follow-up was 2.73 
(interquartile range 1.75, 4.24) years. The majority (96% of those with a type recorded) of 
dementia patients were diagnosed with Alzheimer’s or vascular dementia.
Prevalence and incidence of markers and domains
In the 24 months prior to index (diagnosis) date, 68% of patients had at least one recorded marker 
from the Comorbidity domain and 62% from the Cognitive Function domain (Table 3). Home 
Pressures (4%) and Care (5%) were the least prevalent domains. 
Increased Multimorbidity (based on increase in polypharmacy) was the most common domain 
newly recorded after index date. The highest incidence for the other domains was observed for 
Comorbidity (300/1000py), and Symptoms (230/1000py). Home Pressures had the lowest 
incidence (11/1000py). Prevalence and incidence of markers are reported in Supplementary table 
A1.
Associations of domains with outcomes
74% of patients were hospitalised at least once after index date (430/1000py; 95% CI: 424, 436), 
8% of patients received palliative care (26/1000py; 95% CI: 25, 27) and 37% of patients died 
(115/1000py; 95% CI: 112, 116) during follow-up.
The majority of domains were associated with increased risk of all three outcomes (Table 4). The 
Safety, Comorbidity, and Symptoms domains had the strongest associations with hospital 
admission (hazard ratios (HRs) 1.36 to 1.40), whilst the Severe Neuropsychiatric, Diet/Nutrition, 
Increased Multimorbidity and Daily Functioning domains had strongest associations with 
palliative care (HRs 1.97-2.23) and mortality (HRs 1.92-2.84). The Home Pressures domain was 
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with hospital admission (HR 0.94; 95% CI 0.91, 0.97) and mortality (HR 0.95; 95% CI 0.92, 
0.99). A new or change in dementia-related drug was protective of all three outcomes. 
Accumulation of markers and association with outcomes
In the 12 months after index date, 26,055 (86%) of patients had at least one recorded marker not 
previously recorded, and 5,594 (18%) had at least four domains with a new recorded marker. 
Increasing number of domains with new recorded markers in the one year post-index date was 
linearly associated with increasing risk of hospital admission, palliative care, and mortality (Table 
5). Adjusted HRs when comparing patients with new markers in four or more domains to patients 
with no new recorded markers were 1.24 (95% CI 1.15, 1.33) for hospital admission, 1.87 (95% 
CI 1.62, 2.15) for palliative care, and 1.57 (95% CI 1.47, 1.67) for mortality. Restricting analysis 
to the 15,123 patients diagnosed with dementia from 2010 onwards gave similar strengths of 
association (Supplementary table A2).
Sensitivity analysis exploring the associations between domains recorded in the three years after 
index date with outcomes after three years provided similar results. HRs for the comparison of 
patients with four or more domains with newly recorded markers compared to those with no 
domains were 1.28 (95% CI 1.05, 1.57) for hospital admission, 2.31 (95% CI 1.27, 4.19) for 
palliative care, and 1.64 (95% CI 1.33, 2.03) for mortality (Supplementary table A3). Repeating 
the main analyses using flexible parametric models yielded similar hazard ratios to the Cox 
proportional hazards models (Supplementary table A4).
Discussion
This study of over 30,000 patients with dementia in England aimed to determine the feasibility and 
validity of using markers of dementia-related health as indicators of dementia progression in 
primary care. The study showed that these markers, nested in domains, can be identified in 
primary care EHR, and their recording are associated with recognised endpoint outcomes (hospital 
admission, palliative care, mortality). There was a dose response effect after diagnosis, with an 
increase in risk of poor outcomes as the number of domains for which new markers were recorded 
soon after diagnosis increased. These results demonstrate the potential to identify indicators of 
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Whilst there was variation in their prevalence and incidence, all domains had evidence of  regular 
recording in primary care. However, some individual markers were infrequently recorded and use 
of these markers as indicators of progression may be more feasible at the domain-level. Construct 
validity of the domains was shown through testing of an a priori hypothesis of their association 
with recognised outcomes. A record of a marker such as psychosis within the Severe 
Neuropsychiatric domain increased risk of all outcomes, concordant with a previously identified 
link of behavioural and psychological symptoms and/or anti-psychotic use with risk of 
hospitalisation, nursing home admission, and mortality.28-31 The Increased Multimorbidity, 
Comorbidity, and Symptoms domains were commonly recorded and strongly associated with the 
outcomes; supporting reviews showing increases in comorbidity and health-related burden related 
to poor dementia outcomes.30,32,33 The Care domain showed associations across all outcomes; 
research shows that caregiver coping and stress is associated with poor outcomes in the person 
with dementia,30,34 but also will be reflective of increased provision of care as demonstrated by the 
strong association with palliative care. 
Having a record of a marker (for example, cognitive decline or memory loss) from the Cognitive 
Function domain did not increase risk of the outcomes. One explanation for this might be the level 
of information available. A recent EHR study interrogated narrative text (i.e. clinical notes) to give 
a gradient of cognitive function severity and demonstrated that greater severity is associated with 
mortality.35 A finer grade indicator inclusive of severity would be beneficial in the prediction of 
outcomes. It is also possible cognitive function is less commonly assessed or completed when the 
patient is nearing end of life,36 or that non-cognitive measures are more strongly associated with 
the outcomes used here.
A prescription for a new dementia-related drug was associated with a reduced risk of the 
outcomes. Previous research has shown that use of cholinesterase inhibitors is associated with 
lower mortality in people living with Alzheimer’s disease.37,38 This domain does not take into 
account reason for change or whether change was to a more or less potent drug (related to stage of 
dementia) and therefore may be a less valid indicator of progression. 
The domains of Daily Functioning, Diet/Nutrition, and Safety showed consistent associations with 
our outcomes which concurs with research that has shown associations between functional ability 
and mortality,39 and nutrition and outcomes for those with dementia,40 and is reflective of broader 
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Strengths and Limitations
This study tested a rigorously developed set of domains previously demonstrated to be associated 
with dementia. These domains had been produced via a review of EHR dementia research and 
expert consensus to ensure clinical relevance, mapped to an internationally agreed set of 
outcomes,43 and initial testing within a regional EHR database.10 The CPRD database is broadly 
reflective of the UK population44 with established validity for coding and accuracy of dementia 
diagnosis.45 Whilst measures of frailty designed for use within EHR for the elderly population41 
may overlap with some of the domains, we have derived domains specifically relevant to 
dementia. Future studies could compare our indicators of early progression with general measures 
of frailty. 
Lewy Body and fronto-temporal dementia are associated with greater behavioural disturbance and 
have a faster progression rate to mortality.46,47 Given these types of dementia are less common, 
larger studies should compare indicators of progression by dementia-type. Whilst a person may 
consult with a number of problems, the clinician might decide to only code one problem. A coded 
record for a marker would suggest this was a key reason for a consultation and of importance to 
the clinician and patient/caregiver. Some markers may have been recorded prior to the window of 
time we examined, and whilst most chronic problems should be entered on a regular basis our 
markers reflect recent issues. It is possible that some markers in a domain may be acute in nature 
and have less impact on long-term outcomes. Some markers could be sequentially related (e.g. a 
fall before a fracture), or have a gradient of severity (e.g. neuropsychiatric). This study aimed to 
determine the validity of markers and domains as indicators of progression, and not as 
independent predictors of poor outcome. As such, some of the associations identified with long 
term outcomes may have arisen through chance given the multiple testing, and there may be other 
factors predictive of poor outcome including socio-economic status, ethnicity, social support, 
social care provision;24,30,32,33,48,49 and measures obtainable by invasive testing such as pathogen 
presence (e.g. CSF t-tau) and cortical atrophy (volumetric MRI). Future prognostic research 
should assess which domains improve prediction of long-term outcomes when added to other 
factors. Such research would need to address the potential for collinearity between domains. We 
could not use care home admission as an outcome as this is not comprehensively recorded in 
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changes on instruments designed to measure cognitive function such as the Mini-Mental State 
Examination, commonly used in secondary care dementia services. 
Clinical Relevance
This study is a key step in the development of an approach for managing people with dementia, 
where individuals who are at increased risk of a poor health outcome can be identified in a 
primary care setting. This has potential advantages. First, good information on prognosis can 
contribute to shared decisions on care between patients, carers, and clinicians. Second, “dementia” 
often overshadows other comorbidities within the consultation,50,51 and systematic information 
about such additional concerns contributes to more holistic approaches to care52,53 and better 
healthcare coordination. Third, early identification and targeted care using a stratified-risk 
approach within the primary care population with dementia may offer the possibility of 
intervening to slow progression. This may either be by concentrating resources on patients with 
higher risk of poor outcomes or, if these markers and domains can be shown to be independent 
predictors of poor outcome, by targeting those that are modifiable such as prescribing. 
The increase in risk as number of domains with new markers increases suggests that, whilst some 
domains had stronger associations with outcomes than others, it is the cumulative burden of 
indicators rather than particular combinations which increases risk of poor outcomes. This may 
advocate a simple approach to monitoring early dementia progression based on count of new 
indicators as measured by our domains.  
These indicators may be useful in prognostic models to improve identification of patients with a 
poorer long-term outcome. It may be possible in the future to use these EHR-recorded markers and 
domains as short-term outcomes, reducing the time and costs of research studies, given that 
dementia observational and intervention studies often have to use long-term outcomes such as 
mortality and care home admission.
Conclusions
The validity of potential indicators of progression of dementia derived from primary care EHR is 
supported by their association with recognised outcomes. In particular, early accumulation of these 
indicators after diagnosis is associated with hospital admission, palliative care and mortality. 
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feasibility for use in practice, our study has established a case for future investigation of whether 
this set of markers can be applied to identify patients with a poorer long-term prognosis in order to 
improve their outcomes through stratified care and targeted support. 
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Table 1. List of markers nested within domains with examples
Table 2. Characteristics of patients with dementia, n=30,463
Table 3. Prevalence and incidence of recorded domains 
Table 4. Associations of recording of domains with hospital admission, palliative care, and 
mortality
Table 5. Association of the cumulative number of domains with new recorded markers in the first 
year after diagnosis with hospital admission, palliative care, and mortality after the first year
Figure 1. Time windows for the study
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Table 1. List of markers nested within domains with examples 
Domain Marker Examples 
Care Additional Help Home help, day care 
Care Carer Evidence has a carer in records 
Care Shared Decision Making Shared decision making 
Care Advanced Directive Advanced care planning 
Home Pressures Home Pressures Marital problems, family bereavement/row 




Severe Neuropsychiatric           Severe Mental Illness – 
(b) medication 
Anti-psychotic drug 
Severe Neuropsychiatric           Sectioned Sectioned Form completed/fee paid 
Severe Neuropsychiatric           Crisis Mental crisis plan, referral to crisis team 
Severe Neuropsychiatric           Suicidal Suicidal, high/medium suicide risk 
Neuropsychiatric Depression, Anxiety, Stress – 
(a) coded
 
Depression, anxiety, stress 
Neuropsychiatric Depression, Anxiety, Stress – 
(b) medication 
Anti-depressant drug 
Neuropsychiatric Aggressive Behaviour Aggressive/abusive behaviour 
Neuropsychiatric Sleep Problems –  
(a) coded 
Insomnia, nightmares 
Neuropsychiatric Sleep Problems –  
(b) medication 
Hypnotic/anxiolytic drug 
Neuropsychiatric Behavioural Issues Behavioural problem, disinhibited behaviour 
Neuropsychiatric Low Mood Low mood, tearful, worried, lack of 
concentration 
Neuropsychiatric Wandering Wanders during day/night 
Cognitive Function Cognition Cognitive decline, mentally vague 
Cognitive Function Memory Loss Memory loss, amnesia, poor memory 
Cognitive Function Confusion Confusion, delirium, disorientated 
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Daily Functioning Severe mobility limitation Housebound, chairbound, zimmer frame 
Daily Functioning Mobility – Less Severe 
Limitation 
Mobility poor, walking stick,  gait abnormality 
Daily Functioning Pressure Sore Pressure sore, decubitus ulcer 
Daily Functioning Driving Unfit to drive, advised about driving 
Daily Functioning Difficulty in
 
Eating  Eating problem, dependent for eating 
Daily Functioning Difficulty Handling Finance Needs help handling financial affairs 
Daily Functioning Personal Care Limitation Dependent for dressing/toilet/bathing 
Daily Functioning Stairs Limitation Difficulty managing stairs, need help on stairs 
Safety Fall Recorded fall 
Safety Fracture Recorded fracture (excl. skull) 
Safety Intracranial Injury Skull fracture, concussion 
Safety Safety Assessment Falls risk assessment, home safety advice 
Comorbidity Cardiovascular Myocardial infarction, ischaemic heart disease 
Comorbidity Stroke Stroke, cerebral infarction 
Comorbidity Parkinson’s Disease Parkinson’s disease 
Comorbidity Motor Neurone Disease Motor Neurone disease 
Comorbidity Diabetes Diabetes mellitus (type I or II) 
Comorbidity Epilepsy Epilepsy, grand mal/petiti mal, fit frequency 
Comorbidity Asthma / COPD Asthma, COPD, chronic bronchitis 
Comorbidity Musculoskeletal Pain Osteoarthritis, regional pain, rheumatoid arthritis 
Comorbidity Anaemia Iron deficiency anaemia, Vitamin B12 deficiency 
Comorbidity Ocular Cataract, retinopathy, glaucoma, blindness 
Comorbidity Hypertension Essential hypertension, hypertensive disease 
Comorbidity Candidiasis Candidiasis, thrush 
Symptoms Dizziness Dizziness, vertigo, hypotension, giddiness 
Symptoms Incontinence Incontinent of urine/faeces, urgency micturition 
Symptoms Constipation / IBS Constipation, irritable bowel syndrome (IBS) 
Symptoms Diarrhoea Diarrhoea, loose stools 
Symptoms Urinary Retention of urine, haematuria, dysuria 
Symptoms Neurological Fit (no epilepsy record), blackout 
Symptoms Chest Pain (non-
cardiovascular) 
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Symptoms Oral Health Stomatitis, poor oral hygiene, sore mouth 
Symptoms Swallowing Difficulty swallowing liquids/solids, dysphagia 
Symptoms Hearing Loss Deafness, hearing loss/impairment 
Symptoms “Feels Unwell” Recorded ‘Feels unwell’ 
Diet/Nutrition Poor Diet Advice re diet, high fat diet, dietician referral 
Diet/Nutrition Nutrition Vitamin/iron deficiency, osteomalacia 
Diet/Nutrition Weight Loss Weight decreasing/loss, underweight 
Diet/Nutrition Dietary Supplement Dietary supplement 
Imaging Imaging X-ray, MRI, ECG, DXA, angiogram, CAT scan 
Increased Multimorbidity  Increase in Polypharmacy Increase in count of different drugs prescribed 
Dementia-related Drug Change in Dementia-related 
Drug 
New or changed dementia drug prescribed 
 
Reproduced with permission (to be obtained) from Campbell et al., 2020
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Age:          Mean (SD) 81.6 (7.86) 
Gender:       Male 11,132 (36.5) 
   Female 19,331 (63.5) 
Dementia type:      Alzheimer’s 10,399 (34.1) 
Vascular   7,536 (24.7) 
Lewy Body      478 (1.6) 
Parkinson’s      262 (0.9) 
Frontotemporal        48 (0.2)  
Not recorded or multiple types recorded 11,740 (38.5) 
Body mass index:             Normal 11,044 (36.3) 
   Overweight   7,100 (23.3) 
   Obese   3,373 (11.1) 
   Not recorded    8,946 (29.4) 
Smoking status:      Non-smoker 13,888 (45.6) 
   Current smoker   3,042 (10.0) 
   Ex-smoker   8,493 (27.9) 
   Not recorded   5,040 (16.5) 
Alcohol consumption:      Non-drinker   4,743 (15.6) 
   Current drinker 11,712 (38.5) 
   Ex-drinker      987 (3.2) 
   Not recorded 13,021 (42.7) 
Year of dementia diagnosis:         1998-2009 15,340 (50.4) 
2010-2017 15,123 (49.6) 
Geographical region:         North East      718 (2.4) 
   North West   5,167 (17.0) 
   Yorkshire & The Humber   1,191 (3.9) 
   East Midlands      751 (2.5) 
   West Midlands   3,958 (13.0) 
   East of England   3,287 (10.8) 
   South West   4,133 (13.6) 
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   London   2,954 (9.7) 
   South East Coast   4,225 (13.9) 
Deprivation:          1 Least deprived   6,875 (22.6) 
   2   6,817 (22.4) 
   3   6,568 (21.6) 
   4   5,601 (18.4) 
  5 Most deprived   4,585 (15.1) 
a
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Table 3. Prevalence and incidence of recorded domains  
 
Prevalence in 24m 
before index date 
Incidence
a
 per 1000 person-years in 36m after 
index date 
Domain n (%) n
b
 (%) Incidence (95% CI) 
Care   1,432 (4.7)   5,567 (19.1)   88.17 (85.89, 90.52) 
Home Pressures   1,178 (3.9)      775 (2.7)   11.24 (10.48, 12.06) 
Severe Neuropsychiatric   3,145 (10.3)   5,068 (18.6)   85.64 (83.31, 88.03) 
Neuropsychiatric 13,834 (45.4)   5,922 (35.6) 186.36 (181.68, 191.17) 
Cognitive Function 18,979 (62.3)   3,099 (27.0) 136.78 (132.05, 141.68) 
Daily Functioning   2,558 (8.4)   4,684 (16.8)   76.45 (74.30, 78.68) 
Safety   7,177 (23.6)   6,617 (28.4) 137.93 (134.65, 141.29) 
Comorbidity 20,555 (67.5)   4,919 (49.7) 299.93 (291.67, 308.43) 
Diet/Nutrition   5,388 (17.7)   5,971 (23.8) 112.41 (109.59, 115.29) 
Symptoms 13,921 (45.7)   6,933 (41.9) 230.47 (225.11, 235.96) 
Imaging 14,659 (48.1)   5,481 (34.7) 185.56 (180.72, 190.54) 
Increased Multimorbidity  12,501 (41.0) 13,696 (76.3) 468.54 (460.76, 476.45) 
Dementia-related Drug   1,623 (5.3) 10,335 (35.8) 206.65 (202.71, 210.67) 
a
 Incidence defined as first record of any marker within domain, in those with no marker from 
that domain recorded in 24m prior to index date; 
b
 in those with no record of domain in 24m 
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Table 4. Associations of recording of domains with hospital admission, palliative care, and mortality 








 (95% CI) n
a
 




 (95% CI) n
a
 




 (95% CI) 
Care 4,605 2,684 (58) 1.06 (1.02, 1.11) 6,539 684 (10) 1.64 (1.50, 1.80) 6,999 2,496 (36) 1.63 (1.56, 1.70) 
Home Pressures 1,677 1,196 (71) 1.04 (0.97, 1.10) 1,929 171 (9) 1.23 (1.05, 1.43) 1,953 621 (32) 0.98 (0.91, 1.05) 
Severe Neuropsychiatric 6,006 4,415 (74) 1.26 (1.21, 1.31) 7,890 729 (9) 2.23 (2.05, 2.44) 8,213 4,292 (52) 2.50 (2.41, 2.59) 
Neuropsychiatric 17,511 12,995 (74) 1.25 (1.22, 1.29) 19,500 1,789 (9) 1.78 (1.63, 1.93) 19,756 7,984 (40) 1.73 (1.67, 1.79) 
Cognitive Function 20,895 15,359 (74) 0.94 (0.91, 0.97) 21,891 1,916 (9) 1.04 (0.95, 1.13) 22,078 7,829 (35) 0.95 (0.92, 0.99) 
Daily Functioning 5,018 3,632 (72) 1.26 (1.21, 1.31) 7,043 759 (11) 1.97 (1.81, 2.14) 7,242 3,441 (48) 1.92 (1.85, 1.98) 
Safety 10,322 7,780 (75) 1.40 (1.35, 1.44) 13,596 1,275 (9) 1.67 (1.55, 1.81) 13,794 5,894 (43) 1.73 (1.68, 1.79) 
Comorbidity 23,823 17,976 (75) 1.37 (1.33, 1.42) 25,255 2,249 (9) 1.60 (1.44, 1.79) 25,474 9,724 (38) 1.41 (1.35, 1.47) 
Diet/Nutrition 8,440 5,913 (70) 1.15 (1.12, 1.19) 11,048 1,228 (11) 2.05 (1.90, 2.21) 11,359 5,090 (45) 2.02 (1.95, 2.09) 
Symptoms 18,301 13,824 (76) 1.36 (1.32, 1.40) 20,627 1,940 (9) 1.82 (1.67, 1.99) 20,854 8,343 (40) 1.63 (1.57, 1.69) 
Imaging 17,920 13,369 (75) 1.26 (1.23, 1.30) 19,934 1,833 (9) 1.30 (1.20, 1.42) 20,140 7,316 (36) 1.19 (1.15, 1.23) 
Increased Multimorbidity  19,165 13,419 (70) 1.01 (0.99, 1.04) 24,675 2,111 (9) 2.01 (1.82, 2.21) 25,048 9,887 (39) 2.84 (2.70, 2.98) 
Dementia-related Drug 9,821   6,329 (64) 0.85 (0.83, 0.88) 11,849 927 (8) 0.91 (0.84, 0.99) 11,958 3,471 (29) 0.93 (0.89, 0.96) 
a
 number with recorded marker from domain in 24m before index
 
to earliest of outcome or 36m after index date; 
b 
reference is those with no 
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Table 5. Association of the cumulative number of domains with new recorded markers in the first year after diagnosis with hospital admission, 
palliative care, and mortality after the first year 
Number of domains Number of 
patients 
n (%) with outcome Unadjusted HR (95% CI) Adjusted HR
a
 (95% CI) 
Hospital admission
b 
    
0 3,540  2,216 (62.6)  1.00 1.00 
1 5,702  3,350 (58.8)  0.99 (0.94, 1.05) 1.03 (0.97, 1.08) 
2 4,672 2,797 (59.9)  1.06 (1.00, 1.13) 1.09 (1.03, 1.16) 
3 2,838  1,711 (60.3)  1.13 (1.05, 1.22) 1.16 (1.07, 1.25) 
4+ 2,353  1,375 (58.4)  1.20 (1.12, 1.29) 1.24 (1.15, 1.33) 
Palliative care
c
     
0 4,353   285 (6.6) 1.00 1.00 
1 7,725   528 (6.8) 1.14 (0.99, 1.31) 1.11 (0.96, 1.28) 
2 7,243   554 (7.6) 1.31 (1.14, 1.51) 1.28 (1.11, 1.47) 
3 5,152   410 (7.0) 1.48 (1.25, 1.74) 1.44 (1.22, 1.69) 
4+ 5,411   502 (9.3) 1.96 (1.70, 2.26) 1.87 (1.62, 2.15) 
Mortality     
0 4,408 1,632 (37.0) 1.00 1.00 
1 7,839 2,731 (34.8) 1.01 (0.96, 1.07) 1.05 (0.99, 1.11) 
2 7,369 2,731 (37.1) 1.11 (1.05, 1.18) 1.16 (1.09, 1.23) 
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4+ 5,594 2,394 (42.8) 1.56 (1.46, 1.67) 1.57 (1.47, 1.67) 
a 
HR adjusted for age, gender, BMI, smoking status, alcohol consumption, deprivation, year of index date, and geographical region; 
b 
Excludes 
those with record of hospitalisation in the 12 months after index date; 
c
 Excludes those with record of palliative care in 24 months before index 










Figure 1. Time windows for the study 



















-36 to 0m: Look back period to remove prevalent patients  0 to +12m: Minimum follow-up 
Index date (diagnosis) 
-24 to 0m: Prevalent markers/domains 0 to +36m: Incident markers/domains 
Index date (diagnosis) 
-24m to +36m: Exposed from first record of domain up to earliest of outcome, censoring, or 36m 
Index date (diagnosis) 
0m onwards: follow-up of outcomes until death, end of study, or end of records 
0 to +12m: count of domains with first record of any marker not recorded in 24m pre-index date 
Index date (diagnosis) 
+12m onwards: follow-up of outcomes until death, end of study, or end of records 
ene_14710_f1.pdf
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
